Skip to Content

Edarbi Approval History

  • FDA approved: Yes (First approved February 25th, 2011)
  • Brand name: Edarbi
  • Generic name: azilsartan medoxomil
  • Dosage form: Tablets
  • Company: Takeda Pharmaceutical Company Limited
  • Treatment for: High Blood Pressure

Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.

Development History and FDA Approval Process for Edarbi

Feb 28, 2011Approval FDA Approves Edarbi to Treat High Blood Pressure
Apr 27, 2010Takeda Submits New Drug Application for Azilsartan Medoxomil in the U.S., an Investigational Compound for the Treatment of Hypertension

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.